XFUSION
xFusion Digital Technologies Co., Ltd. (xFusion) dazzled attendees with its top-of-the-range computing products and solutions at the prestigious ISC High Performance 2024 event, hosted at the Congress Center Hamburg in Germany from May 13th to 15th. During the event, xFusion and fellow participants delved into the realms of AI and high performance computing (HPC) to explore their innovative applications and developmental trends, marking a significant convergence of minds and technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516487957/en/
(Photo: xFusion)
Tab Tang , President of the Computing and Expansion at xFusion, delivered a keynote titled "Reinvent HPC in the Era of AI" during the Vendor Roadmap session on the 15th. He illuminated the pivotal role of smart computing in propelling industrial progress, highlighting the cooling challenges arising from high power and computing density, along with sustainability concerns. This necessitates clusters that are not only high-speed and low-latency but also highly reliable and stable. He also emphasized the transformative impact of AI on scientific endeavors, affirming xFusion's commitment to overcoming these challenges through pioneering software and hardware solutions. With a unified platform for both HPC and AI, xFusion aims to invigorate academic research and reshape the landscape of AI-driven HPC.
This year's ISC witnessed xFusion's spotlight on cutting-edge technologies like AI and HPC, presenting computing advancements characterized by openness, intelligence, eco-friendliness, and high-density. This compelling showcase drew attendees eager to delve deeper into these innovations.
At the event, xFusion proudly introduced FusionPoD for AI, a revolutionary rack-scale liquid-cooling cabinet poised to redefine computing paradigms. With its open architecture and support for diverse computing capabilities, FusionPoD for AI integrates groundbreaking architectural, software, and algorithmic innovations. It offers a fresh perspective by embracing multiple ecosystems, diversity, and low-carbon solutions to cater to the demanding requirements of AI large models and other HPC scenarios. This remarkable product delivers an unparalleled computing density of 64 GPUs and features a 100% liquid cooling native design with an impressively low pPUE of 1.06. xFusion also introduced the AI Space accelerator to both partners and customers, promising to expedite their AI application development and deployment.
xFusion stole the spotlight at ISC 2024 by showcasing its FusionOne HPC solution tailored for diverse HPC applications in education, scientific research, and manufacturing simulation. This state-of-the-art offering boasts adaptive characteristics, ensuring efficient, secure, reliable, and easily manageable operations. Notably, FusionOne HPC has already made waves with its deployment in the Weiming No. 2 Cluster at Peking University in 2023. This implementation has addressed the diverse needs of various disciplines, facilitating large-scale data processing and scientific computing while simultaneously reducing power consumption and fostering green research initiatives.
Beyond technological excellence, xFusion leads the charge in delivering comprehensive global business support through its dedicated team, bolstering remote O&M, cluster systems, and open architectural frameworks. Collaborating closely with partners, xFusion drives continuous innovation, fostering a thriving and sustainable HPC ecosystem. The current partnership with Bank Neo Commerce (BNC) in Indonesia marks a pivotal step in revolutionizing digital banking services. By offering agile, secure, and scalable digital infrastructure, xFusion empowers BNC to handle increasing transaction volumes and enhance customer interactions, fueling ongoing innovation and development in local digital banking services. FusionOnline, xFusion's remote intelligent O&M platform, is facilitating remote O&M in Europe, streamlining maintenance efforts while ensuring the long-term stability of user services.
Guided by the vision and mission of "Let Computing Serve You Better", xFusion has expanded its reach to over 100 countries and regions, cementing its status as a premier provider of computing infrastructures and services globally.
Looking to the future, xFusion remains optimistic about the potential of HPC to revolutionize industries and drive transformative innovation. In the era of AI, our ongoing contributions to the advancement of HPC underscore our commitment to shaping a brighter, more efficient, and interconnected world powered by our top-notch computing products and solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516487957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom